Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
Americans agree with Trump that Iran poses threat to United States: poll
Morning Movers: GMS Inc. jumps after report of competing suitors
Bernie Sanders endorses former punk rock musician with history of racist, sexist remarks